Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by O12009on Sep 11, 2024 5:25pm
193 Views
Post# 36219348

RE:RE:Me not smart...

RE:RE:Me not smart... 

GSK discontinues herpes vaccine 

The British pharma said its shot didn’t show desired efficacy in a Phase 2 study. Elsewhere, Pulmovant has plans to advance a drug licensed from Bayer.
GSK will not advance an experimental vaccine for the herpes simplex virus after reviewing data from a Phase 2 trial, the company said Wednesday. While no safety concerns were reported, GSK said the shot did not meet the study’s primary efficacy goal. The British drugmaker plans to “evaluate the totality of all these data” to determine how it can progress research toward a genital herpes vaccine

I wonder if we will soon receive a new release 

<< Previous
Bullboard Posts
Next >>